FN1 and neoplasm: For GBM, Weiss et al. (2020) [347] tested the immunocytokine strategy by linking an L19 antibody, which is specific to a tumor-associated epitope of extracellular fibronectin (expressed in the tumor stroma of most brain cancers, but generally not in healthy tissues), to IL-2, IL-12, or TNF-α, and administering the immunocytokine in immunocompetent mice bearing GL-261 or SMA-560 glioma cell lines.